ipilimumab
Agilent PD-L1 Assay Gets FDA Approval as Metastatic NSCLC Companion Diagnostic
Clinicians will be able to use the assay to help identify patients with metastatic NSCLC for treatment with nivolumab and ipilimumab.
Clinicians will be able to use the assay to help identify patients with metastatic NSCLC for treatment with nivolumab and ipilimumab.